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Contemporary Patterns of Fractional Flow Reserve and Intravascular
Ultrasound Use Among Patients Undergoing Percutaneous Coronary
Intervention in the United Statesta RegistryTo the Editor: The use of fractional flow reserve (FFR) and
intravascular ultrasound (IVUS) to assess intermediate coronary
stenoses (defined as 40% to 70% stenosis) has been associated with
improved procedural and clinical outcomes (1,2) in patients un-
ergoing percutaneous coronary intervention (PCI). Both technol-
gies received a Class IIa recommendation for use in angiographi-
ally intermediate coronary stenoses in the recently published 2011
merican College of Cardiology/American Hospital Association
CI guidelines (3). We undertook an analysis of the CathPCI
egistry data in order to better understand current patterns of use
f both FFR and IVUS associated with PCI of intermediate
esions, and how their use might relate to procedural and patient-
ased outcomes.
The CathPCI Registry is an initiative of the American College
f Cardiology Foundation and the Society for Cardiovascular
ngiography and Interventions and has been previously described
4). We analyzed data for patients undergoing PCI of intermediate
oronary stenoses (defined as a percent diameter stenosis 40%
nd 70%). Patients were excluded if PCI was performed for a
onintermediate stenosis (n  373,320), if they underwent diag-
ostic angiography only (n  1,977), or if they underwent both
FR and IVUS (n  778). We examined data starting from April
009 when version 4 of the CathPCI Registry data collection form
egan to be implemented, as IVUS and FFR use for PCI of
ntermediate stenoses were not collected in earlier versions.
Descriptive statistics on the study population were grouped by
esion assessment (angiography only [AO], FFR, or IVUS).
ategorical variables were presented as percentages, and continu-
us variables were presented as medians along with the interquar-
ile range (IQR). Comparisons between groups were performed
sing Pearson chi-square tests for categorical variables and the
ruskal-Wallis test or Wilcoxon test for continuous variables.
ogistic regression with generalized estimating equations to ac-hospital mortality and procedural success adjusting for baseline
patient characteristics in the CathPCI Registry mortality risk
model. All analyses were performed using SAS version 9.2 (SAS
Institute, Cary, North Carolina).
Data for 61,874 attempted coronary interventions of interme-
diate coronary stenoses performed between April 2009 and Sep-
tember 2010 were available for analysis. Among these, FFR was
used in 3,763 (6.1%) patients, IVUS was used in 12,589 (20.3%)
patients, and 45,522 (73.6%) patients had lesions assessed by AO
(Table 1). Compared with patients who underwent AO, patients
undergoing FFR were more likely to be younger (p  0.0001) and
more frequently male (p  0.0001), with slightly lower rates of
diabetes (p  0.017) and hypertension (p  0.0003), and higher
rates of dyslipidemia (p  0.0001). Patients undergoing IVUS
were younger (p  0.0001) and less frequently male (p  0.0001),
with slightly lower rates of diabetes (p  0.0001) and similar rates
of hypertension (p  0.75) and dyslipidemia (p  0.31).
Patients undergoing FFR were more likely to have had their
procedure performed in a university hospital (p  0.0001) com-
pared with private and community hospitals (p  0.0001) and in a
hospital with a fellowship or residency training program (p 0.0001).
Patients who underwent FFR were less likely to present with an
acute coronary syndrome (ST-segment elevation myocardial in-
farction, non–ST-segment elevation myocardial infarction, and
unstable angina; p  0.0001). Patients who underwent IVUS
were more likely to undergo stress testing prior to the procedure
(p  0.0001). Patients undergoing FFR were more likely to
have had a prior stress test that had negative or equivocal
findings (p  0.0001).
Patients undergoing FFR and/or IVUS were less likely to have
multivessel disease (p  0.0001), and more likely to have a lesion
deemed high risk (p  0.0001). Both the FFR and IVUS cohorts
had longer fluoroscopy times (p  0.0001) and more contrast use
(p  0.0001) as compared with the AO group.
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associated with higher rates of major bleeding (odds ratio [OR]:
1.23; IQR: 1.09 to 1.38; p  0.001), lower rates of in-hospital
death (OR: 0.66; IQR: 0.44 to 0.98; p  0.04), and no difference
in procedural success (OR: 1.10; IQR: 0.97 to 1.26; p  0.14)
compared with AO. No difference between the FFR and AO
groups was seen in adjusted comparisons of mortality (OR: 1.07;
IQR: 0.53 to 2.15; p  0.857), major bleeding (OR: 0.95; IQR:
0.76 to 1.19; p  0.683), or procedural success (OR: 0.97; IQR:
0.76 to 1.25; p  0.836).
This analysis demonstrates that despite a wealth of data
demonstrating the utility of these technologies in the evaluation
of intermediate coronary stenoses (1,2), IVUS (20.3%) and FFR
(6.1%) are used in only a small minority of such cases. The use
of IVUS was likely more common than FFR due to its
demonstrated utility in determining appropriate stent sizing, as
well as the post-implantation evaluation of stent expansion and
apposition. A number of factors probably contributed to these
low rates of use, such as the fact that the catheters used to
perform these lesion assessments are costly and are poorly
reimbursed, if at all. In fact, routine use may provide a financial
disincentive, as the cost of the procedure increases with the use
of the catheters and the reimbursement decreases with less
frequent stent implantation.
After adjustment for comorbidities, IVUS appears to be asso-
ciated with lower rates of in-patient mortality, a finding consistent
with prior data (5). It was also associated with higher rates of major
bleeding, whereas FFR showed no such correlations. Neither
Patient and Procedural CharacteristicsTable 1 Pati nt nd Procedural Characteristics
Angiography Only
(n  45,522)
Median age, yrs 45,522 65.0 (57–73) 3,7
Male, % 28,836 63.35 2,5
Median creatinine clearance* 41,556 64.01 (47.1–82.4) 3,4
Diabetes, % 16,796 36.90 1,3
Hypertension, % 39,047 85.78 3,1
Dyslipidemia, % 38,487 84.55 3,2
Hospital profit type, %
Government 557 1.22
Private/community 39,206 86.13 3,0
University 5,759 12.65 6
Fellowship, internship, or residency
program, %
23,098 50.74 2,1
Admission symptom presentation,† %
Non–acute coronary syndrome 19,844 43.59 1,7
Acute coronary syndrome 25,678 56.41 1,9
Stress or imaging study performed 19,109 41.98 1,8
Outcome of stress or imaging study, %
Positive 15,396 84.22 1,4
Negative 1,783 9.75 2
Equivocal 687 3.76 1
Lesion risk, %
Non-high/non-C 29,671 65.18 2,2
High/C 15,799 34.71 1,4
Multivessel disease, % 20,610 45.27 1,4
Median fluoroscopy time, min 44,872 9.60 (6.1–15.6) 3,7
Median contrast volume, ml 45,403 175 (125–230) 3,7
Values are n, %, and median (interquartile range [IQR]). *Cockroft-Gault calculation. †Acute corona
infarction, and unstable angina. Non–acute coronary syndrome includes no symptoms, atypical ch
FFR  fractional flow reserve; IVUS  intravascular ultrasound.technology was associated with differences in procedural success. cWe were unable to explicitly examine cases where either of these
technologies was used to deem a lesion physiologically insignificant
and PCI was deferred, as these cases are not captured in the
CathPCI Registry dataset. The CathPCI Registry dataset only
records outcomes occurring in the hospital stay during which PCI
was performed. Given that these data were analyzed retrospec-
tively, outcomes associated with the use of IVUS and FFR are
observational and causality cannot be inferred.
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FFR
 3,763) p Value
IVUS
(n  12,589) p Value
63.0 (55–71) 0.0001 12,589 64.0 (56–72) 0.0001
68.32 0.0001 7,439 59.09 0.0001
69.82 (52.9–87.9) 0.0001 11,753 65.36 (48.9–83.5) 0.0001
34.95 0.017 4,363 34.66 0.0001
83.63 0.0003 10,788 85.69 0.745
87.11 0.0001 10,690 84.92 0.313
1.62 0.0001 135 1.07 0.383
80.12 10,856 86.23
18.26 1,598 12.69
58.30 0.0001 6,447 51.21 0.349
49.96 0.0001 5,459 43.36 0.647
53.04 7,130 56.64
49.88 0.0001 6,232 49.50 0.0001
77.61 0.0001 4,918 83.91 0.365
13.14 611 10.42
6.82 223 3.80
60.16 0.0001 7,729 61.39 0.0001
39.76 4,853 38.55
39.49 0.0001 4,463 35.45 0.0001
12.6 (8.8–19) 0.0001 12,459 10.9 (7.3–16.5) 0.0001
200 (154–260) 0.0001 12,553 180 (140–240) 0.0001
rome includes ST-segment elevation myocardial infarction, non–ST-segment elevation myocardial
in, and stable angina. Each p value compares the associated group with angiography only.(n
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Letters to the Editor
Why Permanent Pacemaker
Implantation After Transcatheter
Aortic Valve Implantation
Does Not Affect Long-Term
Clinical Outcome
With interest, we took notice of the paper by Buellesfeld et al. (1)
investigating the impact of permanent pacemaker implantation on
clinical outcome after transcatheter aortic valve implantation
(TAVI) (1). The authors state that periprocedural permanent
pacemaker (PPM) implantation does not affect rate of death,
stroke, and/or myocardial infarction at 12 months compared with
patients with pre-existing PPM or patients without any PPM.
Because the findings of present study seem to contrast with
earlier observations from the MOST (Mode Selection Trial)
study and the DAVID (Dual Chamber and VVI Implantable
Defibrillator) trial, we have some concerns regarding the study
design (2,3).
First of all, Buellesfeld et al. (1) do not provide a power
calculation regarding the study size. Given the relatively low
number of patients, it is likely that the study is under-powered to
detect differences in the primary endpoint of all-cause mortality. It
is plausible than an endpoint combining all-cause mortality with
hospitalization for worsening of heart failure would have resulted
in different outcome between the groups. Indeed, the MOST and
DAVID trials, using similar endpoints, demonstrated that chronic
right ventricular pacing is associated with occurrence of heart
failure (2,3).Second, the PPM implantation strategy in the present study
seems rather liberal and early, with almost three-quarters of
implantations occurring within 3 days after TAVI. As early
atrioventricular conduction disorders post-TAVI are known to
recover over time (4–6), a considerable number of patients would
ave received a PPM unnecessarily. Although scarce, there is some
vidence that during longer follow-up of TAVI-related PPM
mplantations, patients show no or limited pacemaker dependency
7) (unpublished data van der Boon RM, van Mieghem NM,
heuns DA, et al., 2012). Due to alterations in pacing mode, these
atients are not exposed to the unbeneficial effects of chronic right
entricle pacing.
We recently compared the impact of TAVI-induced left bundle
ranch block (LBBB) on all-cause mortality during long-term
ollow-up. In a cohort of 679 patients, all-cause mortality was
ignificantly higher among patients with TAVI-induced LBBB
ompared with patients without LBBB. Interestingly, the mortal-
ty rate among patients receiving PPM after TAVI was comparable
o that of patients without TAVI-induced LBBB. This discrep-
ncy could be explained by the low percentage of cumulative
entricular pacing in the PPM group (8).
In conclusion, in the present study by Buellesfeld et al. (1),
atient classification might be problematic as the post-TAVI PPM
atients are principally heterogeneous and are not all exposed to
he risks of (continuous) right ventricular pacing, which might
xplain the findings of the current study. We agree with the
uthors that larger-scaled studies are needed to further investigate
he impact of PPM after TAVI.
Patrick Houthuizen, MD
obert M. A. van der Boon, MS
een A. F. M. Van Garsse, MD
rits W. Prinzen, PhD
eter de Jaegere, MD, PhD
Department of Cardiology
atharina Hospital
ostbus 1350
indhoven 5602 ZA
he Netherlands
-mail: cardiology@houthuizen.be
http://dx.doi.org/10.1016/j.jacc.2012.07.058
lease note: Dr. Van Garsse is a proctor for Edwards LifeSciences. Dr. Prinzen has
eceived research grants from Medtronic, EBR Systems, Philips, Enopace, and
erck-Sharp & Dohme. Dr. de Jaegere is a proctor for Medtronic CoreValve. All
ther authors have reported that they have no relationships relevant to the contents of
his paper to disclose.
EFERENCES
1. Buellesfeld L, Stortecky S, Heg D, et al. Impact of permanent
pacemaker implantation on clinical outcome among patients undergo-
ing transcatheter aortic valve implantation. J Am Coll Cardiol 2012;
60:493–501.
2. Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or
ventricular backup pacing in patients with an implantable defibrillator:
the Dual Chamber and VVI Implantable Defibrillator (DAVID) trial.
JAMA 2002;288:3115–23.
3. Sweeney MO, Hellkamp AS, Ellenbogen K, et al. Adverse effect of
ventricular pacing on heart failure and atrial fibrillation among patients
with normal baseline QRS duration in a clinical trial of pacemaker
therapy for sinus node dysfunction. Circulation 2003;107:2932–7.
